Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Piflufolastat F 18: Diagnostic First Approval.

Literature DB >> 34292532

Piflufolastat F 18: Diagnostic First Approval.

Abstract

Piflufolastat F 18 (PYLARIFY®) is an 18F-labelled diagnostic imaging agent that has been developed by Progenics Pharmaceuticals Inc., a Lantheus company, for positron emission tomography (PET) that targets prostate-specific membrane antigen (PSMA). Piflufolastat F 18 was approved in the USA on 27 May 2021 for PET of PSMA positive lesions in men with prostate cancer with suspected metastasis who are candidates for initial definitive therapy or with suspected recurrence based on elevated serum prostate specific antigen (PSA) level. This article summarizes the milestones in the development of piflufolastat F 18 leading to this approval as a radioactive diagnostic agent in prostate cancer.

Entities: Chemical

Mesh：

Substances：

Year: 2021 PMID： 34292532 DOI： 10.1007/s40291-021-00548-0

Source DB: PubMed Journal: Mol Diagn Ther ISSN： 1177-1062 Impact factor: 4.074

4 in total

1. Reply by Authors.

Authors: Kenneth J Pienta; Michael A Gorin; Steven P Rowe; Peter R Carroll; Frédéric Pouliot; Stephan Probst; Lawrence Saperstein; Mark A Preston; Ajjai S Alva; Akash Patnaik; Jeremy C Durack; Nancy Stambler; Tess Lin; Jessica Jensen; Vivien Wong; Barry A Siegel; Michael J Morris
Journal: J Urol Date: 2021-04-15 Impact factor: 7.450

2. Imaging of prostate cancer with positron emission tomography.

Authors: Michael E Zimmerman; Alexa R Meyer; Steven P Rowe; Michael A Gorin
Journal: Clin Adv Hematol Oncol Date: 2019-08

3. SUVs Are Adequate Measures of Lesional ¹⁸F-DCFPyL Uptake in Patients with Low Prostate Cancer Disease Burden.

Authors: Yves J L Bodar; Berend P F Koene; Bernard H E Jansen; Matthijs C F Cysouw; Dennie Meijer; N Harry Hendrikse; André N Vis; Ronald Boellaard; Daniela E Oprea-Lager
Journal: J Nucl Med Date: 2021-01-28 Impact factor: 10.057

Review 4. PSMA-Targeting Positron Emission Agents for Imaging Solid Tumors Other Than Non-Prostate Carcinoma: A Systematic Review.

Authors: Christophe Van de Wiele; Mike Sathekge; Bart de Spiegeleer; Pieter Jan de Jonghe; Laurence Beels; Alex Maes
Journal: Int J Mol Sci Date: 2019-10-02 Impact factor: 5.923

4 in total

7 in total

1. Prostate-Specific Membrane Antigen Is a Biomarker for Residual Disease following Neoadjuvant Intense Androgen Deprivation Therapy in Prostate Cancer.

Authors: John R Bright; Rosina T Lis; Anson T Ku; Nicholas T Terrigino; Nichelle C Whitlock; Shana Y Trostel; Nicole V Carrabba; Stephanie A Harmon; Baris Turkbey; Scott Wilkinson; Adam G Sowalsky
Journal: J Urol Date: 2022-03-01 Impact factor: 7.600

Review 2. A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2021.

Authors: Gizem Kayki-Mutlu; Zinnet Sevval Aksoyalp; Leszek Wojnowski; Martin C Michel
Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2022-05-11 Impact factor: 3.195

3. Fluorine-18 Labeled Urea-Based Ligands Targeting Prostate-Specific Membrane Antigen (PSMA) with Increased Tumor and Decreased Renal Uptake.

Authors: Falguni Basuli; Tim E Phelps; Xiang Zhang; Carolyn C Woodroofe; Jyoti Roy; Peter L Choyke; Rolf E Swenson; Elaine M Jagoda
Journal: Pharmaceuticals (Basel) Date: 2022-05-13

Piflufolastat F 18: Diagnostic First Approval.

1. Reply by Authors.

2. Imaging of prostate cancer with positron emission tomography.

3. SUVs Are Adequate Measures of Lesional ¹⁸F-DCFPyL Uptake in Patients with Low Prostate Cancer Disease Burden.

Review 4. PSMA-Targeting Positron Emission Agents for Imaging Solid Tumors Other Than Non-Prostate Carcinoma: A Systematic Review.

1. Prostate-Specific Membrane Antigen Is a Biomarker for Residual Disease following Neoadjuvant Intense Androgen Deprivation Therapy in Prostate Cancer.

Review 2. A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2021.

3. Fluorine-18 Labeled Urea-Based Ligands Targeting Prostate-Specific Membrane Antigen (PSMA) with Increased Tumor and Decreased Renal Uptake.

4. Prostate-Specific Membrane Antigen-Targeted Turn-on Probe for Imaging Cargo Release in Prostate Cancer Cells.

5. Editorial: Exploring the Potential of PSMA-PET Imaging on Personalized Prostate Cancer Treatment.

Review 6. 2021 FDA TIDES (Peptides and Oligonucleotides) Harvest.

Review 7. New Halogen-Containing Drugs Approved by FDA in 2021: An Overview on Their Syntheses and Pharmaceutical Use.